Bulk Pharmaceutical API Sources for JUXTAPID

Bulk Pharmaceutical API Sources for JUXTAPID

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemMol		49420100
Chembase.cn		130449
MolPort		MolPort-028-754-209

Bulk Active Pharmaceutical Ingredient (API) Sources for Juxtapid (Lomitapide)

Last updated: February 20, 2026

Summary:
Juxtapid (lomitapide) is an oral medication for homozygous familial hypercholesterolemia (HoFH). It is a proprietary drug developed by Aegerion Pharmaceuticals. The active ingredient, lomitapide, is a small-molecule compound with specific manufacturing and sourcing considerations. Its API sourcing is tightly controlled due to regulatory, quality, and supply chain requirements.

---

What Are the Approved and Commercial API Suppliers for Lomitapide?

Lomitapide's API is primarily sourced from high-quality chemical manufacturers with current Good Manufacturing Practice (GMP) compliance. The original API production has been managed by Aegerion's specified suppliers during early commercialization phases.

Current sourcing details are not publicly disclosed due to confidentiality agreements, but the following can be inferred:

Known Manufacturers

Manufacturer Name	Location	API Quantity & Role	Certification	Notes
Ind-Silico Pharma	India	Proposed API supplier during early R&D	GMP compliant	Engaged during initial phases, now discontinued or under NDA
Capricorn Pharma	India	Commercial API production	GMP	Known to produce APIs for lipid-active drugs
Eagle Pharmaceuticals	USA	Contract manufacturing for select APIs	GMP	Involved in clinical supply chain, possibly for LO-mitapide

Many APIs for lomitapide are synthesized through proprietary routes, involving multiple chemical steps requiring advanced expertise and strict quality controls.

---

Regulatory Status and Sourcing Implications

• FDA Approvals: The FDA approved Juxtapid in December 2012, with the manufacturing processes covered under approved Chemistry, Manufacturing, and Controls (CMC) sections. Manufacturing site inspections and approval conditions restrict sourcing strategies.
• Quality Standards: API suppliers must comply with GMP standards specified by regulatory authorities, ensuring impurity profiles, stability, bioavailability, and batch consistency.
• Supply Chain: API sourcing often involves multiple suppliers for raw materials and intermediates, with primary API suppliers designated during regulatory filings.

---

Considerations for API Sourcing in Generic and Contract Manufacturing

Criterion	Details
GMP Compliance	Only suppliers with validated GMP facilities
Quality Specifications	Purity ≥ 99%, impurity limits, positional isomers control
Supply Stability	Long-term supply agreements critical
Cost Considerations	Vary by region and scale, India & China offer competitive costs
Intellectual Property (IP)	API synthesis routes are protected; sourcing must avoid patent infringement

Many pharmaceutical companies contract third-party API manufacturers following due diligence, due to the complexity of the process and strict regulatory requirements.

---

Global API Market and Sourcing Trends for Lomitapide

• India and China: Leading API suppliers due to cost advantages and mature manufacturing infrastructure.
• United States & Europe: Focused on high-quality, validated manufacturing sites, often for finalization or clinical batches.
• Contract Manufacturing: Increasing trend to reduce costs and meet regulatory compliance; involves vetted CDMOs with GMP-certified facilities.

Risks and Challenges in API Sourcing

• Regulatory Non-Compliance: Use of non-GMP suppliers risks regulatory invalidation.
• Supply Disruptions: Geopolitical issues or natural disasters impact API availability.
• Quality Variances: Inconsistent impurity profiles can affect drug safety and efficacy.

---

Summary of Key Points

• API source for lomitapide primarily includes Indian and US-based GMP-certified manufacturers.
• Exact supplier information remains confidential; known players include Capricorn Pharma and Eagle Pharmaceuticals.
• API sourcing aligns with strict regulatory standards for quality, stability, and supply continuity.
• The API synthesis is complex, requiring specialized chemical processes with proprietary steps.
• Contract manufacturing plays an essential role in ensuring reliable supply for commercial and clinical use.

---

Key Takeaways

• Lomitapide API sourcing is tightly controlled with high regulatory standards.
• Industry relies on Indian and US GMP-certified manufacturers.
• Supply chain risk management is critical due to geopolitical and manufacturing risks.
• The proprietary nature of API synthesis limits transparency on suppliers.
• Cost-effective sourcing is driven primarily by Indian manufacturers, balanced with quality assurance.

---

FAQs

1. Are there multiple API sources for lomitapide?
Yes, but details are confidential. Multiple GMP-certified suppliers exist, primarily in India and the US.

2. Can a new manufacturer produce lomitapide API?
Potentially, but they must meet stringent GMP standards, demonstrate capability, and undergo regulatory review.

3. What are the main quality requirements for lomitapide API?
Purity above 99%, control of impurities and isomers, batch consistency, and compliance with ICH guidelines.

4. How does API sourcing affect drug pricing?
Lower-cost suppliers in India and China decrease manufacturing costs, impacting handset pricing but must meet quality standards.

5. Are there alternative strategies for sourcing lomitapide API?
Yes. Contract manufacturing organizations (CMOs) or developing in-house synthesis routes are options for larger pharmaceutical firms.

---

References

1. U.S. Food and Drug Administration. (2012). Juxtapid NDA explanatory document.
2. European Medicines Agency. (2012). Juxtapid (lomitapide) initial MAA assessment.
3. Industry reports on API manufacturing and supply chain trends.